Despite its acceptance as standard of care neary 25 years ago, barriers still exist that preclude patients from receiving breast conserving therapy (BCT), according to research presented at the ASCO 2014 Breast Cancer Symposium.
Researchers have developed a breathalyzer that can detect lung cancer and assess whether it is early or advanced, according to findings presented at the 2014 annual meeting of the American Society of Clinical Oncology.
New treatment options are available for advanced melanoma, according to three studies presented at the annual ASCO meeting.
In patients with triple-negative breast cancer (TNBC) who are BRCA1/2 mutation carriers, pathologic complete response (pCR) is not a surrogate for relapse-free survival, in contrast to those with non-BRCA mutations.
Immediately integrating cancer treatment and palliative care might improve survival at 1 year in patients with advanced cancers, suggest findings from the ENABLE III randomized controlled trial, presented at the 2014 ASCO Annual Meeting.
For patients with non-small-cell lung cancer who have relapsed after initial treatment, the addition of the anti-angiogenesis drug ramucirumab to standard docetaxel chemotherapy extends survival.
Enzalutamide, an oral androgen-receptor inhibitor, is superior to placebo for the treatment of metastatic prostate cancer before chemotherapy, according a study.
For premenopausal women with hormone receptor-negative early breast cancer treated with chemotherapy, goserelin can preserve ovarian function, according to a study presented at the annual ASCO meeting.
Family members caring for patients with advanced cancer benefit from early initiation of phone-based training and support.
In patients with breast cancer who had previously received monthly intravenous bisphosphonate therapy for bone metastases for a year or longer, maintenance zoledronic acid administered every 12 weeks was noninferior to every 4 weeks.
